Aspira Pathlab Diagnostics Ltd vs Poly Medicure Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 24, 2026

Key Highlights

The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20 . The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Poly Medicure Ltd changed from 57.7 on March 2021 to 37.5 on March 2026 . This represents a CAGR of -6.93% over 6 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe Market Cap of Poly Medicure Ltd changed from ₹ 7839 crore on March 2021 to ₹ 12069 crore on March 2026 . This represents a CAGR of 7.46% over 6 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Poly Medicure Ltd for the Jun '26 is ₹ 560.34 crore as compare to the Mar '26 revenue of ₹ 553.98 crore. This represent the growth of 1.15% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Poly Medicure Ltd for the Jun '26 is ₹ 160.06 crore as compare to the Mar '26 ebitda of ₹ 129.86 crore. This represent the growth of 23.26% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Poly Medicure Ltd changed from ₹ 74.04 crore to ₹ 85.27 crore over 9 quarters. This represents a CAGR of 6.48% The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Poly Medicure Ltd changed from 18.51 % on March 2021 to 10.56 % on March 2026 . This represents a CAGR of -8.93% over 6 years .

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
ASDL is a leading pathology specialist, with Pan-India presence.
It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

About Poly Medicure Ltd

Poly Medicure Limited was incorporated on March 30, 1995.
The Company is a producer of Medical Devices.
It manufactures and supply, a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices and others. The Company's product portfolio comprises of more than 130 SKUs of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others.
It currently operate 10 manufacturing facilities across India, China, Egypt and Italy.

FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Poly Medicure Ltd

Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Poly Medicure Ltd?

Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Poly Medicure Ltd is 14,628 Cr

What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Poly Medicure Ltd?

The stock performance of Aspira Pathlab & Diagnostics Ltd and Poly Medicure Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Poly Medicure Ltd?

As of October 24, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Poly Medicure Ltd stock price is INR ₹1443.2.

How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Poly Medicure Ltd compare?

To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Poly Medicure Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.